To the Editor: The review article by Reck and Rabe (Aug. 31 issue)1 and other guidelines recommend pathological evaluation of the mediastinal nodes in patients with non–small-cell lung cancer (NSCLC) who are found to have abnormal mediastinal or hilar nodes on computed tomography (CT) or positron-emission tomography with CT (PET-CT). However, this practice may need to be reconsidered. Studies have indicated that surgery in patients with pathologically confirmed nodal involvement (stage N2 disease) has little proven clinical benefit and should be performed judiciously. However, a recent systematic review suggested that overall survival was longer among patients with N2 disease who . . .

中文翻译：

---

晚期非小细胞肺癌

致编者：Reck和Rabe的评论文章（8月31日发行）1和其他指南建议对发现患有纵隔或肺门异常的非小细胞肺癌（NSCLC）患者的纵隔淋巴结进行病理评估计算机断层扫描（CT）或具有CT的正电子发射断层扫描（PET-CT）上的节点。但是，可能需要重新考虑这种做法。研究表明，经病理学证实为淋巴结转移（N2期疾病）的患者，手术的临床获益很少，应谨慎行事。但是，最近的一项系统评价表明，患有N2疾病的患者的总体生存期更长。。。